# Research Methodology Framework
## Long COVID Systematic Review and Evidence Synthesis

### 1. Research Design

#### 1.1 Study Type
**Systematic Review with Mixed Methods Synthesis**
- Quantitative evidence synthesis (meta-analysis where applicable)
- Qualitative thematic analysis
- Mixed methods integration using convergent design
- Grey literature incorporation

#### 1.2 Theoretical Framework
**Biopsychosocial Model Application**
- Biological mechanisms and pathophysiology
- Psychological impacts and manifestations
- Social determinants and healthcare access
- Environmental and occupational factors

#### 1.3 Research Questions

**Primary Research Questions**:
1. What are the established pathophysiological mechanisms of Long COVID?
2. What is the current evidence for treatment efficacy across different symptom clusters?
3. How do international clinical guidelines compare in their recommendations?
4. What are the identified gaps in current research and clinical practice?

**Secondary Research Questions**:
1. What are the risk factors for developing Long COVID?
2. How does Long COVID presentation vary across populations?
3. What are the economic and quality of life impacts?
4. What emerging therapies show promise?

### 2. Search Strategy

#### 2.1 Database Selection

**Primary Databases**:
- PubMed/MEDLINE
- Embase
- Cochrane Library
- Web of Science
- Scopus

**Specialized Databases**:
- ClinicalTrials.gov
- WHO International Clinical Trials Registry
- FDA Drug Database
- EMA Database
- NICE Evidence

**Grey Literature Sources**:
- medRxiv/bioRxiv preprints
- Government reports
- Professional organization guidelines
- Patient advocacy publications
- Conference proceedings

#### 2.2 Search Terms and Boolean Logic

**Core Search Strategy**:
```
("Long COVID" OR "Post-COVID-19 syndrome" OR "Post-acute sequelae of SARS-CoV-2" OR "PASC" OR "Post-COVID conditions" OR "Chronic COVID syndrome")
AND
("Treatment" OR "Therapy" OR "Management" OR "Intervention" OR "Clinical guidelines" OR "Pathophysiology" OR "Mechanism" OR "Diagnosis" OR "Prognosis")
AND
("Clinical trial" OR "Systematic review" OR "Meta-analysis" OR "Cohort study" OR "Case-control study" OR "Guidelines" OR "Consensus statement")
```

**Filters Applied**:
- Publication date: December 2019 - Present
- Languages: English, Spanish, French, German, Chinese (with translation)
- Study types: As specified above
- Age groups: All ages (with subgroup analysis)

#### 2.3 Inclusion and Exclusion Criteria

**Inclusion Criteria**:
1. Studies addressing Long COVID (symptoms >4 weeks post-infection)
2. Original research, systematic reviews, clinical guidelines
3. Clear methodology and outcome measures
4. Peer-reviewed or official guideline publications
5. Minimum sample size: n≥10 for original studies

**Exclusion Criteria**:
1. Single case reports (unless reporting novel mechanisms)
2. Opinion pieces without systematic methodology
3. Duplicate publications
4. Studies without clear Long COVID definition
5. Animal studies (unless directly translatable mechanisms)

### 3. Data Management

#### 3.1 Reference Management System

**Primary Tool**: Zotero with cloud sync
- Automated citation importing
- Duplicate detection
- Team library sharing
- Tag-based organization
- PDF annotation system

**Organizational Structure**:
```
/Long-COVID-Research-Library
  /01-Primary-Literature
    /Pathophysiology
    /Clinical-Studies
    /Epidemiology
  /02-Guidelines
    /International
    /National
    /Professional-Societies
  /03-Treatments
    /FDA-Approved
    /Off-Label
    /Investigational
  /04-Grey-Literature
  /05-Excluded-Studies
```

#### 3.2 Data Extraction Protocol

**Standardized Extraction Fields**:

1. **Study Identification**
   - First author, year
   - DOI/PMID
   - Country of origin
   - Funding source

2. **Study Characteristics**
   - Design type
   - Sample size
   - Duration
   - Setting

3. **Population**
   - Demographics
   - COVID severity
   - Comorbidities
   - Vaccination status

4. **Interventions** (if applicable)
   - Type
   - Dosage/frequency
   - Duration
   - Comparators

5. **Outcomes**
   - Primary outcomes
   - Secondary outcomes
   - Adverse events
   - Quality of life measures

6. **Results**
   - Effect sizes
   - Confidence intervals
   - P-values
   - Clinical significance

7. **Quality Assessment**
   - Risk of bias
   - Limitations
   - Generalizability

### 4. Quality Assessment

#### 4.1 Quality Assessment Tools

**By Study Type**:

| Study Type | Assessment Tool | Domains |
|------------|----------------|----------|
| RCTs | Cochrane RoB 2.0 | Selection, performance, detection, attrition, reporting bias |
| Observational | ROBINS-I | Confounding, selection, classification, deviations, missing data, measurement, reporting |
| Systematic Reviews | AMSTAR 2 | 16 critical domains |
| Guidelines | AGREE II | Scope, stakeholder involvement, rigor, clarity, applicability, editorial independence |
| Qualitative | CASP | 10 questions covering validity, results, relevance |

#### 4.2 Evidence Grading

**GRADE Framework Application**:

1. **Quality of Evidence**:
   - High: Further research unlikely to change confidence
   - Moderate: Further research likely to impact confidence
   - Low: Further research very likely to impact confidence
   - Very Low: Any estimate of effect uncertain

2. **Strength of Recommendation**:
   - Strong: Benefits clearly outweigh risks
   - Weak: Benefits closely balanced with risks
   - No recommendation: Insufficient evidence

### 5. Synthesis Methods

#### 5.1 Quantitative Synthesis

**Meta-Analysis Criteria**:
- Clinical homogeneity assessment
- Statistical heterogeneity (I² statistic)
- Random effects model (DerSimonian-Laird)
- Sensitivity analyses
- Publication bias assessment (funnel plots, Egger's test)

**Software**: R (meta, metafor packages) or RevMan 5.4

#### 5.2 Qualitative Synthesis

**Thematic Analysis Approach**:
1. Familiarization with data
2. Initial code generation
3. Theme identification
4. Theme review and refinement
5. Theme definition and naming
6. Report production

**Software**: NVivo or ATLAS.ti

#### 5.3 Mixed Methods Integration

**Convergent Design Process**:
1. Parallel data analysis
2. Separate synthesis
3. Integration at interpretation
4. Joint display creation
5. Meta-inferences development

### 6. Reporting Standards

#### 6.1 PRISMA Guidelines

**Required Elements**:
- PRISMA flow diagram
- Complete search strategy
- Study characteristics table
- Risk of bias summary
- Forest plots (if meta-analysis)
- Evidence summary tables

#### 6.2 Transparency and Reproducibility

**Documentation Requirements**:
- Protocol registration (PROSPERO)
- Search strategy reproducibility
- Data extraction forms
- Analysis code availability
- Raw data availability (where permitted)
- PRISMA checklist completion

### 7. Team Collaboration

#### 7.1 Role-Specific Protocols

**Dual Independent Review Process**:
- Title/abstract screening: 2 reviewers
- Full-text review: 2 reviewers
- Data extraction: 1 extractor, 1 verifier
- Quality assessment: 2 independent assessors
- Discrepancy resolution: Third reviewer or consensus

#### 7.2 Calibration Exercises

**Training Protocol**:
1. Pilot screening (50 abstracts)
2. Kappa calculation (target ≥0.8)
3. Discrepancy discussion
4. Protocol refinement
5. Final calibration confirmation

### 8. Timeline and Milestones

#### 8.1 Critical Path

| Week | Milestone | Deliverable | Quality Gate |
|------|-----------|-------------|--------------|
| 1-2 | Protocol finalization | Registered protocol | Team consensus |
| 3 | Search execution | Search results | Reproducibility check |
| 4 | Title/abstract screening | Included studies list | Inter-rater reliability |
| 5-6 | Full-text review | Final inclusion list | Consensus achieved |
| 7-8 | Data extraction | Completed database | Verification complete |
| 9 | Quality assessment | Quality scores | Calibration confirmed |
| 10 | Synthesis | Analysis outputs | Statistical review |
| 11 | Report drafting | First draft | Internal review |
| 12 | Finalization | Final report | QA approval |

#### 8.2 Contingency Planning

**Buffer Time Allocation**:
- 20% buffer for each phase
- Parallel processing where possible
- Escalation protocol for delays
- Resource reallocation options

### 9. Statistical Analysis Plan

#### 9.1 Descriptive Statistics
- Study characteristics summary
- Population demographics
- Outcome frequencies
- Missing data patterns

#### 9.2 Inferential Statistics
- Pooled effect estimates
- Heterogeneity assessment
- Subgroup analyses
- Meta-regression (if applicable)
- Sensitivity analyses

#### 9.3 Software and Version Control
- Statistical software: R 4.0+ or Stata 17
- Version control: Git repository
- Analysis scripts: Documented and reproducible
- Output management: Organized file structure

### 10. Dissemination Strategy

#### 10.1 Academic Outputs
- Peer-reviewed publication (target journal identified)
- Conference presentations
- Poster presentations
- Webinar series

#### 10.2 Clinical Translation
- Clinical practice guidelines input
- Provider education materials
- Patient information resources
- Policy briefs

#### 10.3 Public Engagement
- Plain language summary
- Infographics
- Social media strategy
- Press release (if warranted)